Abrégé

The present invention provides a pharmaceutical composition and health functional food for preventing or treating cerebral infarction, the composition comprising micro RNA-382-5P (miR-382-5P). The miR-382-5P is involved in interneuron adhesion, nervous system development, vocal behavior, neurotrophin signaling pathways, dopaminergic synapses, P13K-AKT signaling pathways, and apoptosis. The composition according to the present invention has an excellent effect in reducing the extent or severity of cerebral infarction.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester 
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
• A23L 33/13 - Acides nucléiques ou leurs dérivés

Abrégé

The present invention provides a pharmaceutical composition and health functional food for preventing or treating cerebral infarction, the composition comprising micro RNA-412-5P (miR-412-5P). The miR-382-5P is involved in nervous system development, neurotrophin signaling pathways, Hippo signaling pathways, axon guidance, and Wnt/PCP pathways. The composition according to the present invention has an excellent effect in reducing the extent or severity of cerebral infarction.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
• A23L 33/13 - Acides nucléiques ou leurs dérivés

Abrégé

A functional food composition for immune enhancement, comprising a persicaria senticosa extract as an active ingredient, according to the present invention, increased the proliferation of mouse spleen cells and the secretion of immune cytokines such as IL-2, IL-4, IL-10, and IFN-γ in vitro, and increased the secretion of immune cytokines such as IL-2, IL-4, and IL-10 in mouse blood in vivo, whereby the effect of activating immune enhancement has been confirmed. Thus, the functional food composition for immune enhancement can be utilized as a functional food composition useful for immune enhancement.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23P 10/20 - Agglomération; Granulation; Mise en comprimés
• A61K 36/704 - Polygonum, p.ex. renouée des oiseaux
• A61P 37/04 - Immunostimulants

Abrégé

The present invention relates to a composition for ameliorating, preventing or treating a viral infectious disease, the composition comprising an Ecklonia cava extract or dieckol as an active ingredient, and the like. The composition of the present invention is derived from a natural substance that has been proven to be highly safe for a long time and has the advantage of having very few or no side effects when used, and has effective proliferation inhibitory activity against SARS-CoV-2 and variants thereof, and thus is expected to be used as an effective antiviral agent derived from a natural substance.

Classes IPC  ?

• A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p.ex. éthers en couronne, guanadrel
• A61K 36/03 - Phaeophycota ou phaeophyta (algues brunes), p.ex. Fucus
• A61P 31/12 - Antiviraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention relates to a composition for preventing or treating benign prostatic hyperplasia, comprising fruit extracts of Elaeagnus multiflora Thunb. The fruit extracts of Elaeagnus multiflora Thunb. according to the present invention inhibited the production of 5-alpha reductase-2, prostate-specific antigen (PSA), and 5-alpha-reductase-2 in vitro, and also suppressed the enlargement of prostate tissues and the contents of 5-alpha reductase and prostate-specific antigen (PSA) in a testosterone-induced prostatic hyperplasia rat model, thereby enhancing the excellent effect of preventing or suppressing prostatic hyperplasia even in animal models, and thus have industrial applicability.

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 13/08 - Médicaments pour le traitement des troubles du système urinaire de la prostate

Abrégé

The present invention relates to a composition and the like containing Ecklonia cava extract or phlorofucofuroeckol A as an active ingredient for ameliorating, preventing, or treating viral infections. The composition of the present invention is expected to be an effective naturally-derived anti-viral agent as the composition is derived from a natural substance long proven to be highly safe, has the benefit of having little or no adverse effects when used, and has activity that effectively inhibits proliferation of SARS-CoV-2 and variants thereof.

Classes IPC  ?

• A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p.ex. éthers en couronne, guanadrel
• A61K 36/03 - Phaeophycota ou phaeophyta (algues brunes), p.ex. Fucus
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

in vitroin vitro generation of 5 alpha reductase, dihydrotestosterone, and androgen receptor (AR). In a benign prostatic hyperplasia rat model induced by testosterone, the composition inhibits prostate tissue enlargement, inhibits 5-alpha reductase generation in prostate hypertrophy tissue, relieves enlarged epithelial cells, and inhibits polyps, thus exhibiting an excellent benign prostatic hyperplasia prevention or inhibition effect in animal models.

Classes IPC  ?

• A61K 36/45 - Ericaceae ou Vacciniaceae (famille de la bruyère ou de la myrtille), p.ex. myrtille, canneberge ou airelle
• A61P 13/08 - Médicaments pour le traitement des troubles du système urinaire de la prostate
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

Ilex integraIlex integraIlex integra Thunb. leaf extract as an active ingredient according to the present invention decreased protein expression levels of ERK and AKT and increased expression levels of p-EKR and p-AKT in the hippocampus (HC) and prefrontal cortex (PFC)of the chronic restraint stress (CRS)-induced mice, compared to controls, thereby exhibiting prophylactic or therapeutic effects on stress disorders. In addition, there is the advantage of enabling the production of products for preventing sleep disorders, such as sound sleep disorder, sleep maintenance insomnia, nocturnal awakening, early wakening, insomnia, circadian rhythm sleep disorder, parasomnias, etc.

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 25/20 - Hypnotiques; Sédatifs
• A61P 25/24 - Antidépresseurs
• A61P 25/22 - Anxiolytiques
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

A pharmaceutical composition and a health functional food composition for alleviating eye fatigue containing, as active ingredients, compounds, particularly, luteolin-7-O-diglucuronide and apigenin-7-O-diglucuronide isolated from a Perilla frutescens (L.) Britton var. acuta (Thunb.) Kudo leaf extract have an effect of alleviating eye fatigue by increasing the contents of NO and cGMP associated with relaxation of ciliary smooth muscle cells isolated from rat's eyes and decreasing the content of [Ca2+]i, and increasing cGMP which is a factor associated with relaxation of the ciliary smooth muscle through an animal experiment. As a result, the luteolin-7-O-diglucuronide and apigenin-7-O-diglucuronide compounds extracted from Perilla frutescens (L.) Britton var. acuta (Thunb.) Kudo may be usefully used as a pharmaceutical composition and a health functional food composition having an eye fatigue alleviating effect as a Korean natural resource.

Classes IPC  ?

• A61K 36/535 - Perilla (Perilla nankinensis)
• A61P 27/02 - Agents ophtalmiques
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine

Abrégé

The present invention can provide a preventative cosmetic composition for safely improving the skin barrier and moisturization without toxicity or side effects, by using Vaccinium bacteaum Thunb., which is a natural resource native to Korea, wherein the composition contains a Vaccinium bacteaum Thunb. leaf extract as an active ingredient.

Classes IPC  ?

• A61K 8/9789 - Magnoliopsida [dicotylédones]
• A61Q 19/00 - Préparations pour les soins de la peau

Abrégé

The present invention relates to a pharmaceutical composition for enhancing immunity, comprising an extract of Crepideastrum denticulatum as an active ingredient, and provides a functional food composition for enhancing immunity, which can enhance biological immunity by promoting the formation of NO and inducing the formation of cytokines, IL-2, IL-10, and IFN-γ.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 5/20 - Préparation ou traitement des aliments ou produits alimentaires en général; Aliments ou produits alimentaires ainsi obtenus; Leurs matériaux Élimination de constituants indésirables, p.ex. désodorisation ou détoxication

Abrégé

The present invention relates to a composition for preventing or treating benign prostatic hyperplasia, comprising fruit extracts of Elaeagnus multiflora Thunb.. The fruit extracts of Elaeagnus multiflora Thunb. according to the present invention inhibited the production of 5-alpha reductase-2, prostate-specific antigen (PSA), and 5-alpha-reductase-2 in vitro, and also suppressed the enlargement of prostate tissues and the contents of 5-alpha reductase and prostate-specific antigen (PSA) in a testosterone-induced prostatic hyperplasia rat model, thereby enhancing the excellent effect of preventing or suppressing prostatic hyperplasia even in animal models, and thus have industrial applicability.

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 13/08 - Médicaments pour le traitement des troubles du système urinaire de la prostate
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

Bacillus velezensisBacillus velezensisBacillus velezensis L2 (KCCM 12498P) screened in the present invention is used as a starter for aekjeot fermentation to minimize the generation of histamines, which are substances associated with allergic reactions or inflammation, and increase the generation amount of total nitrogen and amino nitrogen, so that flavor can be improved.

Classes IPC  ?

• C12N 1/20 - Bactéries; Leurs milieux de culture
• A23L 13/40 - Produits à base de viande; Farine de viande; Leur préparation et leur traitement contenant des additifs
• C12R 1/07 - Bacillus

Abrégé

Persicaria senticosaPersicaria senticosa(Meisn.)H.Gross ex Nakai extract as an active ingredient, the cosmetic composition having the effect of inhibiting and protecting damage to keratinocytes (HaCaT cells) induced by ultraviolet light. In addition, the cosmetic composition exhibits the effects of reducing UVB-induced oxidative damage in skin cells irradiated with ultraviolet light and protecting cells from the consequent cell death (MAP kinase inhibitory effect), and has an excellent MMP-1 production inhibitory effect and an excellent collagen synthesis enhancement effect, and thus can be used as a cosmetic composition for preventing and ameliorating skin aging caused by ultraviolet light, which can be safely used without toxicity and side effects.

Abrégé

The present invention relates to a health functional food composition for improving cognitive skills and memory, comprising a fruit or leaf extract of Quercus acuta Thunb as an active ingredient. The composition of the present invention may be used as a health functional food composition for a regular normal person, enabling improving cognitive skills or memory by improving neuroplasticity and synaptic reorganization, and not by improving cognitive skills and memory associated with degenerative brain disease.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 5/20 - Préparation ou traitement des aliments ou produits alimentaires en général; Aliments ou produits alimentaires ainsi obtenus; Leurs matériaux Élimination de constituants indésirables, p.ex. désodorisation ou détoxication

Abrégé

The present invention relates to a cosmetic composition comprising a Quercus acuta Thunb extract as an active ingredient for preventing and alleviating ultraviolet light-caused skin aging. It was observed that when treated with the control group UVB, HaCaT cells, which are a human epidermal keratinocyte line, increased in collagenase activity, compared to a normal group whereas, for a test group treated with UVB and a Quercus acuta Thunb extract together, collagenase activity decreased as the concentration of the Quercus acuta Thunb extract increased. Thus, the cosmetic composition for prevention and alleviation of ultraviolet light-caused skin aging according to the present invention has an excellent inhibitory effect on collagenase activity and can be used safely without toxicity and adverse effects.

Classes IPC  ?

• A61K 8/9789 - Magnoliopsida [dicotylédones]
• A61Q 19/00 - Préparations pour les soins de la peau
• A61Q 19/08 - Préparations contre le vieillissement

Abrégé

The present invention relates to a method for mass purification of highly pure cordycepin from Cordyceps militaris by using recycling liquid chromatography and provides a mass purification method for highly pure cordycepin, wherein naturally dried Cordyceps militaris is treated by hot water extraction, lyophilized, and developed using a 5-10% methanol solvent at a flow rate of 120 ml/min.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 19/00 - Produits à base de fruits ou de légumes; Leur préparation ou leur traitement
• A23L 3/44 - Lyophilisation
• B01D 15/26 - Adsorption sélective, p.ex. chromatographie caractérisée par le mécanisme de séparation

Abrégé

The present invention relates to a pharmaceutical composition and functional cosmetic composition for skin regeneration comprising, as an active ingredient, a Porphyra dentata extract in which the single compound dehydrated P-334, which is an active ingredient contained in Porphyra dentata, is enhanced. Single compounds P-334 and DP-334 isolated from the seaweed according to the present invention promoted the growth of keratinocytes (HACAT cells). By confirming that DP-334, which is a single compound isolated from the seaweed, increases the protein and mRNA expression of the epidermal growth factor receptor (EGFR), which is a receptor for sensing epidermal growth hormones, thereby having a skin regeneration effect, the single compound DP-334 isolated from the seaweed according to the present invention can be used in a pharmaceutical composition and functional cosmetic compound for skin regeneration, which are effective in skin regeneration.

Classes IPC  ?

• A61K 36/04 - Rhodophycota ou rhodophyta (algues rouges), p.ex. Porphyra
• A61K 31/198 - Alpha-amino-acides, p.ex. alanine, acide édétique (EDTA)
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• A61K 8/9717 - Rhodophycota ou Rhodophyta [algues rouges], p.ex. Porphyra
• A61K 8/44 - Acides aminocarboxyliques ou leurs dérivés, p.ex. acides aminocarboxyliques contenant du soufre; Leurs sels, esters ou dérivés N-acylés
• A61Q 19/00 - Préparations pour les soins de la peau

Abrégé

Vaccinium bracteatum Thunb., which is natural resource of Korea, so that the reduction of manufacturing and production costs and the import substitution and export effects can be expected through the replacement of a raw material for preparation with a plant inhabiting in nature.

Classes IPC  ?

• A61K 36/45 - Ericaceae ou Vacciniaceae (famille de la bruyère ou de la myrtille), p.ex. myrtille, canneberge ou airelle
• A61P 25/22 - Anxiolytiques
• A61P 25/24 - Antidépresseurs

Abrégé

Provided is a functional health food product exhibiting eye fatigue prevention and alleviation by means of luteolin-7-O-diglucuronide and apigenin-7-O-diglucuronide compounds contained in a Perilla frutescens (L.) Britton var. acuta (Thunb.) Kudo extract. It has been confirmed that the compounds of luteolin-7-O-diglucuronide and apigenin-7-O-diglucuronide are contained in equal amounts as active ingredients of freeze-dried and spray-dried products of the leaves of Perilla frutescens (L.) Britton var. acuta (Thunb.) Kudo of the present invention. In ciliary muscle cells isolated from rat eyes (rCSMCs), the amounts of NO and cGMP, which are associated with eye relaxation, are increased and the amount of [Ca2+i ion is decreased. In addition, the amount of cGMP increased in animal experiments. These compounds increase the amount of cGMP in ciliary muscle cells isolated from rat eyes, thereby being usable in a functional health food composition useful for the prevention and alleviation of eye fatigue.

Classes IPC  ?

• A61K 36/535 - Perilla (Perilla nankinensis)
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/48 - Préparations en capsules, p.ex. de gélatine, de chocolat
• A61P 27/02 - Agents ophtalmiques

Abrégé

Vaccinium bracteatum Thunb. fruits, which are Korean natural resources, so as to be safely usable without toxicity and side effects.

Classes IPC  ?

• A61K 36/45 - Ericaceae ou Vacciniaceae (famille de la bruyère ou de la myrtille), p.ex. myrtille, canneberge ou airelle
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61P 25/24 - Antidépresseurs
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

Stauntonia hexaphyllaStauntonia hexaphyllaStauntonia hexaphyllaStauntonia hexaphylla leaf-derived extract or the fractional purified product, a caffeic acid compound and a novel flavonoid compound separated from the extract or the fractional purified product.

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61K 31/216 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p.ex. bénactizyne, clofibrate
• A61K 31/35 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

Vaccinium bracteatum Thunb.Vaccinium bracteatum Thunb.Vaccinium bracteatum Thunb. fruit which is a natural food.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention provides a pharmaceutical composition for prevention or treatment of a stress disease and depression, the pharmaceutical composition being safely usable without toxicity and side effects by using an extract of leaves of Vaccinium bracteatum Thunb., which is natural resource of Korea, so that the reduction of manufacturing and production costs and the import substitution and export effects can be expected through the replacement of a raw material for preparation with a plant inhabiting in nature.

Classes IPC  ?

• A61K 36/45 - Ericaceae ou Vacciniaceae (famille de la bruyère ou de la myrtille), p.ex. myrtille, canneberge ou airelle
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/48 - Préparations en capsules, p.ex. de gélatine, de chocolat
• A61K 9/16 - Agglomérés; Granulés; Microbilles
• A61K 9/08 - Solutions

Abrégé

The present invention provides a pharmaceutical composition for preventing or ameliorating andropause syndrome, comprising an Elaeagnus multiflora Thunb. extract as an active ingredient, wherein the Elaeagnus multiflora Thunb. extract is extracted by using any one selected from among water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. Thus, Elaeagnus multiflora Thunb. which is a natural resource of Korea is used as a resource, and it is possible to safely provide a composition for preventing, ameliorating, or treating andropause syndrome without toxicity or side effects.

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs

Abrégé

The present invention relates to an immunopotentiating pharmaceutical composition having an Elaeagnus multriflora Thunb. leaf extract as an effective ingredient and provides an immunopotentiating pharmaceutical composition or functional food composition which can potentiate immunity in vivo by activating immune cells directly antagonizing the cytokine production induction of interlukin-2 (IL-2), interlukine-4 (IL-4), or interlukine-10 (IL-10), and tumor cells.

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention relates to a novel flavonoid compound separated from a Stauntonia hexaphylla leaf, and a pharmaceutical or food composition, for promoting bone formation or cartilage formation or for preventing, remedying or treating bone or cartilage destruction such as rheumatoid arthritis, having same as an active ingredient. More specifically, the present invention relates to a pharmaceutical or food composition comprising as an active ingredient a compound represented by chemical formula (1) having a bone or cartilage formation promoting effect or a bone or cartilage destruction preventing, remedying or treating effect by means of inhibiting osteoclast differentiation and promoting collagen type II and aggrecan expression and production.

Classes IPC  ?

• C07H 17/07 - Benzo[b]pyranones-4
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs

Abrégé

The present invention relates to a novel caffeic acid compound separated from a Stauntonia hexaphylla leaf, and a pharmaceutical or food composition, for promoting bone formation or cartilage formation or for preventing, remedying or treating bone or cartilage destruction such as rheumatoid arthritis, having same as an active ingredient. More specifically, the present invention relates to a pharmaceutical or food composition comprising as an active ingredient a compound represented by chemical formula (1) having a bone or cartilage formation promoting effect or a bone or cartilage destruction preventing, remedying or treating effect by means of inhibiting osteoclast differentiation and promoting collagen type II and aggrecan expression and production.

Classes IPC  ?

• C07H 15/203 - Carbocycles monocycliques autres que des cycles cyclohexane; Systèmes carbocycliques bicycliques
• A61K 31/7034 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs

Abrégé

The present invention provides a health functional food composition and a pharmaceutical composition for preventing and alleviating depression, both compositions using an extract of Vaccinium bracteatum Thunb. fruits, which are Korean natural resources, so as to be safely usable without toxicity and side effects.

Classes IPC  ?

• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23P 10/00 - Mise en forme ou traitement des produits alimentaires caractérisés par les produits

Abrégé

The present invention relates to a method for preparing abalone chips, comprising the steps of: (S10) washing abalone; (S20) steaming the washed abalone; (S30) separating the shell, the viscera, and the teeth from the steamed abalone; (S40) crushing the separated abalone flesh; (S50) mixing starch into the crushed abalone flesh and kneading the same; (S60) dividing and panning the dough; and (S70) baking the panned dough in an oven.

Classes IPC  ?

• A23G 3/36 - Sucreries, confiseries ou massepain; Procédés pour leur fabrication caractérisés par la composition
• A22C 29/00 - Traitement des coquillages ou crustacés, p.ex. huîtres, homards
• A23L 17/40 - Crustacés ou coquillages
• A23L 27/10 - ALIMENTS, PRODUITS ALIMENTAIRES OU BOISSONS NON ALCOOLISÉES NON COUVERTS PAR LES SOUS-CLASSES OU ; LEUR PRÉPARATION OU TRAITEMENT, p.ex. CUISSON, MODIFICATION DES QUALITÉS NUTRITIVES, TRAITEMENT PHYSIQUE ; CONSERVATION DES ALIMENTS OU PRODUITS ALIMENTAIRES EN GÉNÉRAL Édulcorants artificiels; Sels de table; Substituts diététiques du sel; Leur préparation ou leur traitement Épices, agents aromatiques ou condiments naturels; Leurs extraits
• A23G 3/34 - Sucreries, confiseries ou massepain; Procédés pour leur fabrication

Abrégé

Provided is a high value-added functional health food acting on hangover relief, containing, as an active ingredient, an extract of a Stauntonia hexaphylla fruit, which is a Korean natural resource. The composition for relieving hangovers, of the present invention, has an excellent effect of relieving hangovers while not having side effects on the human body, and thus a beverage for preventing and relieving hangovers, containing the same as an active ingredient, is easy to take, and can be stored for a long time, thereby being usable for relieving hangovers before and after drinking.

Classes IPC  ?

• A23L 21/25 - Miel; Succédanés du miel
• A23L 2/38 - Autres boissons non alcoolisées
• A61K 36/71 - Ranunculaceae (famille du bouton d'or), p.ex. pied d'alouette, hépatique, hydrastis, ancolie

Abrégé

The present invention relates to a high value-added functional pharmaceutical composition, which has a liver protection function for alcoholic liver damage and can be safely used without toxicity and side effects by using a hot water extract of a Stauntonia hexaphylla fruit, which is a Korean natural resource. The pharmaceutical composition, of the present invention, containing, as an active ingredient, a crude extract or a nonpolar soluble extract of a Stauntonia hexaphylla fruit has an excellent liver protection function for alcoholic liver damage while having no side effects on the human body, and thus the crude extract of a Stauntonia hexaphylla fruit, which is a natural material, is used as an active ingredient, thereby being usable in liver protection for alcoholic liver damage and being safe without side effects even when taken for a long time.

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61K 36/71 - Ranunculaceae (famille du bouton d'or), p.ex. pied d'alouette, hépatique, hydrastis, ancolie

Abrégé

stauntonia hexaphylla leaf extract according to the present invention as an active ingredient may be used as a medicine for periodontitis or osteoporosis to treat or prevent periodontitis or osteoporosis.

Classes IPC  ?

• A61K 36/71 - Ranunculaceae (famille du bouton d'or), p.ex. pied d'alouette, hépatique, hydrastis, ancolie
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 9/16 - Agglomérés; Granulés; Microbilles
• A61K 9/20 - Pilules, pastilles ou comprimés

Produits et services

Abalone, not live; Abalone, namely, frozen, dried, preserved with salt and preserved abalone

Abrégé

The present specification relates to a composition for promoting osteoblast or cartilage cell differentiation. More particularly, the present specification relates to a composition, which includes stauntonia hexaphylla leaf extract that may be safely used without toxicity and side effects by using a natural ingredient, for promoting bone (tissue) formation to be used for suppressing and treating bone and cartilage tissue damage. A pharmaceutical composition including the stauntonia hexaphylla leaf extract according to the present specification as an active ingredient may be used as a medicine for periodontitis or osteoporosis to treat or prevent periodontitis or osteoporosis.

Classes IPC  ?

• A61K 36/71 - Ranunculaceae (famille du bouton d'or), p.ex. pied d'alouette, hépatique, hydrastis, ancolie
• A61K 9/16 - Agglomérés; Granulés; Microbilles
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette

Abrégé

The present invention relates to a composition for promoting osteoblast differentiation or cartilage cell differentiation, and more specifically, to a composition for promoting bone (tissue) formation to be used for preventing and treating bone and cartilage damage, containing a Stauntonia hexaphylla leaf extract enabled to be safely used without toxicity and side effects by using natural ingredients. The pharmaceutical composition of the present invention, containing Stauntonia hexaphylla leaf extract as an active ingredient, can be used as a periodontitis or osteoporosis medicine for treating or preventing periodontitis or osteoporosis.

Classes IPC  ?

• A61K 36/71 - Ranunculaceae (famille du bouton d'or), p.ex. pied d'alouette, hépatique, hydrastis, ancolie
• A61K 9/16 - Agglomérés; Granulés; Microbilles
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette

Abrégé

Provided is a high value-added functional dietary supplement for cough relief or the discharge of phlegm, containing a hot water extract of Dendropanax morbiferus H.Lev. leaves, which are Korean natural resources, as an active ingredient. Provided is a composition for cough relief or the discharge of phlegm which is safe without side effects even if being taken for a long time since a natural material is used, and contains a crude extract of Dendropanax morbiferus H.Lev. leaves solubilized and extracted from any one of water, methanol, ethanol, propanol, isopropanol, butanol or a mixture solvent thereof, and an aprotic extract from any one of hexane, chloroform, dichloromethane and ethyl acetate as an aprotic solvent, as active ingredients.

Classes IPC  ?

• A61K 36/25 - Araliaceae (famille du ginseng), p.ex. lierre, aralia, schefflera ou tétrapanax
• A61P 11/10 - Expectorants
• A61P 11/14 - Antitussifs

Abrégé

Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)

Abrégé

The present invention relates to a composition comprising leaf extract of Dendropanax morbifera, and to a pharmaceutical composition and health functional food comprising powder or extract obtainable by extracting and concentrating Dendropanax morbifera leaves using various solvents for preventing and treating bowl diseases such as constipation through the activation of enterokinesia. The leaf extract of Dendropanax morbifera according to the present invention is verified as having excellent effects of promoting enterokinesia, treating intestinal disorders and improving constipation in a rat experiment. The leaf extract of Dendropanax morbifera according to the present invention can be valuably used as a pharmaceutical composition and health functional food for preventing and treating bowl disease such as constipation through the activation of enterokinesia.

Classes IPC  ?

• A61K 36/25 - Araliaceae (famille du ginseng), p.ex. lierre, aralia, schefflera ou tétrapanax
• A61K 9/48 - Préparations en capsules, p.ex. de gélatine, de chocolat
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/16 - Agglomérés; Granulés; Microbilles
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

Abrégé

The present invention relates to a method for extracting Acorus calamus var. angustatus-derived β-asarone using supercritical fluid extraction, and more specifically, to a method for extracting Acorus calamus var. angustatus oil containing a large amount of β-asarone, comprising the steps of: grinding Acorus calamus var. angustatus; extracting the ground Acorus calamus var. angustatus through supercritical fluid extraction using supercritical carbon dioxide and a co-solvent at 40-60 ℃ and at 200-400 bar; and concentrating the Acorus calamus var. angustatus extract. Accordingly, it is possible to provide an essential oil containing a large amount of β-asarone from Acorus calamus var. angustatus extracted by the extraction method.

Classes IPC  ?

• C11B 1/10 - Production des graisses ou huiles à partir de matières premières par extraction
• C11B 1/04 - Traitement préliminaire des matières premières végétales

Abrégé

The present invention relates to a composition comprising a Dendropanax morbiferus extract for improving male sexual function. One result observed from an experiment of a Dendropanax morbiferus extract using the corpus cavernosum penis of a rabbit shows that a water extract, an ethanol extract, and an aqueous solution of an ethanol extract of the Dendropanax morbifera leaf and a fraction of a hot water extract of Dendropanax morbifera, which is fractionated by using any one selected from the group consisting of butanol, hexane, ethyl acetate, and chloroform as a fractional solvent, relaxes the smooth muscle of the corpus cavernosum penis, thereby enhancing the erection of the penis, and particularly improving male sexual function by showing the significant relaxing effect on the corpus cavernosum penis of a rabbit. Therefore, the composition comprising the Dendropanax morbiferus extract or the Dendropanax morbiferus fraction as an active ingredient for improving male sexual function can be used as a functional food composition for improving male sexual function by alleviating or preventing erectile dysfunction and can also be used as a pharmaceutical composition for treating or preventing male sexual diseases such as erectile dysfunction, premature ejaculation, inhibited ejaculation, or sexual impotence.

Classes IPC  ?

• A61K 36/25 - Araliaceae (famille du ginseng), p.ex. lierre, aralia, schefflera ou tétrapanax
• A61P 15/10 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour l'impuissance
• A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs

Abrégé

The present invention relates to a composition comprising Hovenia dulcis extract as an active ingredient for the treatment or prevention of intestinal disorders. Particularly, in a constipation-inducing experimental model, and in an intestinal motility test model, Hovenia dulcis, an active ingredient of the present invention, induced the activation of intestinal function and alleviated constipation by activating the secretion of mucus in the intestine of an animal model by using charcoal. Further, since Hovenia dulcis is derived from a natural substance, side effects or toxic problems are less likely to occur. Therefore, the present invention provides a pharmaceutical composition or functional food composition which improves intestinal function and alleviates intestinal disorders, and which is especially effective and safe in the prevention and treatment of constipation.

Classes IPC  ?

• A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p.ex. médicaments traditionnels à base de plantes
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

Abrégé

Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylia leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.

Classes IPC  ?

• A61K 36/71 - Ranunculaceae (famille du bouton d'or), p.ex. pied d'alouette, hépatique, hydrastis, ancolie
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.

Classes IPC  ?

• A61K 36/71 - Ranunculaceae (famille du bouton d'or), p.ex. pied d'alouette, hépatique, hydrastis, ancolie
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to a fever medicine containing a Stauntonia hexaphylla leaf extract as an active ingredient. The Stuantonia hexaphylla leaf extract according to the present invention does not have cytotoxicity, and is completed by verifying a superior fever alleviation effect even when compared to existing fever medicines having fever alleviation effects. The composition for alleviating fever containing the Stauntonia hexaphylla leaf extract as the active ingredient has an excellent fever alleviation effect.

Classes IPC  ?

• A61K 36/71 - Ranunculaceae (famille du bouton d'or), p.ex. pied d'alouette, hépatique, hydrastis, ancolie
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to a pharmaceutical composition for preventing and treating neurodegenerative diseases, and more particularly, to a pharmaceutical composition and functional health food for preventing and treating neurodegenerative diseases, which contain essential oil extracts obtained from needleleaf trees, such as Chamaecyparis obtuse as active ingredients. When administered, the pharmaceutical composition of the present invention exhibits effects of improving cognition ability, preventing neurodegenerative diseases, and improving and treating symptoms of neurodegenerative diseases. Particularly, the pharmaceutical composition of the present invention improves cognition ability and motor coordination for neurodegenerative diseases caused by beta-amyloid, and therefore, may be valuably used for preventing and treating neurodegenerative diseases and may improve learning ability and memory of people without neurodegenerative diseases.

Classes IPC  ?

• A61K 36/14 - Cupressaceae (famille du cyprès), p.ex. genévrier ou cyprès
• A61K 36/15 - Pinaceae (famille du pin), p.ex. pin ou cèdre
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A23L 1/29 - Modification de la qualité nutritive des aliments; Produits diététiques ( A23L 1/09 a priorité;substituts diététiques du sel A23L 1/22)

Abrégé

The present invention relates to a composition containing Oenanthe javanica extract as an active ingredient for preventing or treating learning disabilities or memory disorders, and to a method for preparing same. More particularly, the present invention relates to a composition which can be used as a pharmaceutical composition or functional health food and which is prepared by extracting an active ingredient from Oenanthe javanica, which is an edible herb, wherein the active ingredient provides the function of preventing acetylcholinesterase (AChE) from being activated, or the function of preventing or treating learning disability or memory disorder.

Classes IPC  ?

• A61K 36/23 - Apiaceae ou Umbelliferae (famille de la carotte), p.ex. aneth, cerfeuil, coriandre ou cumin
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The present invention relates to a liposome composition including liposomes encapsulated with a pneumococcal capsular polysaccharide antigen, a method of preparing the composition, and a usage of the composition as a pneumonia vaccine, wherein the liposome composition comprises: a phospholipid selected from phosphatidylcholine and phosphatidylethanolamine; and a cholesterol or derivative thereof selected from cholesterol and cholesterol hemisuccinate, wherein the liposome does not include a carrier protein.

Classes IPC  ?

• A61K 9/127 - Liposomes
• A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p.ex. polyphosphates inorganiques
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
• A61P 31/04 - Agents antibactériens